Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Albutamol Plus
- Development stage
- Unknown
- Lead developer
- Centaur Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Albutamol Plus is an oral combination therapy developed by Centaur Pharmaceuticals for the treatment of respiratory conditions such as asthma, bronchitis, and chronic obstructive pulmonary disease (COPD). It is formulated as a fixed-dose combination containing three active ingredients: salbutamol (a short-acting beta-2 adrenergic receptor agonist), etofylline (a xanthine derivative that acts as a phosphodiesterase inhibitor and adenosine receptor antagonist), and bromhexine (a mucolytic agent). Together, these components provide synergistic therapeutic effects: salbutamol and etofylline act as bronchodilators to relax airway smooth muscle and improve airflow, while bromhexine reduces mucus viscosity and enhances mucociliary clearance to facilitate expectoration. Albutamol Plus is approved and marketed in India.
- Brand names
- Albutamol Plus
- Other names
- bromhexine + etofylline + salbutamolsalbutamol + etofylline + bromhexine
02
Targets
ADOR (Adenosine receptors)ADRB2 (β2)PDE (Phosphodiesterase family)
Beyond the preview
Go deeper on Albutamol Plus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Albutamol Plus.